中文 | English
Return
Total: 9 , 1/1
Show Home Prev Next End page: GO
Author:(Zhan-Miao YI)

1. Strategies for containment of antimicrobial resistance by WHO and some countries around the world

Zhan-Miao YI

Chinese Pharmaceutical Journal 2014;49(3):253-256

2. Pharmacy education innovation in pharmacy practice

Zhan-Miao YI

Chinese Pharmaceutical Journal 2014;49(24):2227-2229

3.Oxcarbazepine and carbamazepine in the treatment of primary trigeminal neuralgia:systemic review and Meta-analysis

Yi-Ming LUO ; Jie-Hui XU ; Zhan-Miao YI ; Suo-Di ZHAI

The Chinese Journal of Clinical Pharmacology 2014;(12):1130-1134

4.Analysis of the efficacy of cinepazide maleate injection on acute cerebral ischemic stroke

Si-Yuan ZHU ; Ying-Ying YAN ; Zhan-Miao YI ; Suo-Di ZHAI

The Chinese Journal of Clinical Pharmacology 2017;33(20):2081-2083,2088

5.Construction of BRCC3 gene knockout mice and preliminary analysis of the pheno-type

Yang XIAO ; Guang-Ming REN ; Yi-Qun ZHAN ; Miao YU ; Chang-Yan LI ; Xiao-Ming YANG ; Rong-Hua YIN

Military Medical Sciences 2018;42(1):44-48

6.Children with idiopathic hypogonadotropic hypogonadism: clinical data analysis and mutations analysis of KAL1 and FGFR1 gene.

Miao QIN ; Chunxiu GONG ; Zhan QI ; Di WU ; Min LIU ; Yi GU ; Bingyan CAO ; Wenjing LI ; Xuejun LIANG

Chinese Journal of Pediatrics 2014;52(12):942-947

7.Single-agent maintenance therapy in non-small cell lung cancer: a systematic review and meta-analysis.

Dong-Mei YUAN ; Shu-Zhen WEI ; Yan-Ling LÜ ; Yan ZHANG ; Xiao-Hui MIAO ; Ping ZHAN ; Li-Ke YU ; Yi SHI ; Yong SONG

Chinese Medical Journal 2012;125(17):3143-3149

8.Analysis of Therapeutic Efficacy and Adverse Prognostic Factors of Secondary Central Nervous System Lymphoma

Ning WANG ; Fei-Li CHEN ; Yi-Lan HUANG ; Xin-Miao JIANG ; Xiao-Juan WEI ; Si-Chu LIU ; Yan TENG ; Lu PAN ; Ling HUANG ; Han-Guo GUO ; Zhan-Li LIANG ; Wen-Yu LI

Journal of Experimental Hematology 2024;32(5):1420-1426

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 9 , 1/1 Show Home Prev Next End page: GO